A Phase 2 interventional study of L608 and Placebo in Systemic Sclerosis, sponsored by Pharmosa Biopharm Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Pharmosa Biopharm Inc. · Phase 2, Interventional, and Treatment
This trial is designed to evaluate the efficacy and safety of L608 compared to placebo in patients with SSc-DU.
This trial is designed to evaluate the efficacy and safety of L608 compared to placebo in patients with SSc-DU, with the primary objective of exploring the effect of L608 on reducing the time to healing of the cardinal DU.
The trial utilizes a double-blind, placebo-controlled, parallel group design. Approximately 40 eligible participants will be enrolled and randomized 1:1 to L608 or placebo groups at baseline.
610 studies on the registry are indexed under Scleroderma, Systemic; 218 are open to participants now.
This study's planned enrollment of 40 is close to the median of 37 across 446 interventional studies indexed under Scleroderma, Systemic.
Browse Scleroderma, Systemic studies →Pharmosa Biopharm Inc. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Drug: L608
Drug: Placebo
Participants will receive L608 TID over 28 consecutive days.
Participants will receive Placebo TID over 28 consecutive days.
Time to healing of the cardinal DU
Time to healing of the cardinal DU compared with placebo
Time frame: up to 12 weeks
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pharmosa Biopharm Inc.